Skip to content

A Clinical Study on the Combined Use of Zhuang Medicine Acupoint Application and Shengxuebao Compound in the Treatment of Acute Peptic Ulcers with Bleeding

A Clinical Study on the Combined Use of Zhuang Medicine Acupoint Application and Shengxuebao Compound in the Treatment of Acute Peptic Ulcers with Bleeding

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000757
Enrollment
Unknown
Registered
2026-03-27
Start date
2024-07-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peptic Ulcer Bleeding

Interventions

Control Group:The control group received routine Western medical treatment, including fasting, oxygen therapy, electrocardiographic monitoring, acid suppression and gastric protection, fluid resuscita
Shengxuebao Group:In addition to the control group treatment, after dietary opening, Shengxuebao Compound Syrup (ingredients: Polygonum multiflorum, Ligustrum lucidum, Mulberry fruit, Eclipta prostrat
Joint Group:In addition to the control group treatment, upon admission, Zhuang medical acupoint patch application was administered (Jianli point, Shenque point, bilateral Sanjiao, bilateral Chengman p

Sponsors

Nanning Wuming District Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 75 Years

Inclusion criteria

Inclusion criteria: If the patient meets all of the following criteria, they may be included in the study: 1. Meets the diagnostic criteria for peptic ulcers; 2. Age: 20-75 years old; 3. Moderate anemia (60g/L < HGB < 90g/L); 4. Has clinical symptoms of hematemesis and/or melena; 5. Diagnosed with peptic ulcers after endoscopic examination and ruled out other causes of gastrointestinal bleeding; 6. Voluntarily signed a written informed consent form prior to enrollment.

Exclusion criteria

Exclusion criteria: Patients meeting any of the following criteria will be excluded from this study: 1. Severe dysfunction of major organs (heart, liver, kidney); 2. Non-ulcerative gastrointestinal bleeding: Bleeding caused by esophageal or gastric varices, or by other non-ulcerative etiologies; 3. Malignant tumors: Presence of gastric malignancy or other systemic malignancies; 4. Mental or cognitive disorders: Patients with mental illness or cognitive impairments that prevent cooperation with treatment; 5. Allergic reactions: History of drug allergies; 6. Skin diseases: Extensive skin damage or severe allergic skin reactions; 7. Special populations: Women who are pregnant, breastfeeding, or planning to conceive during the study period.

Design outcomes

Primary

MeasureTime frame
hemoglobin;

Secondary

MeasureTime frame
Hematocrit;Urea nitrogen;Duration of abdominal pain;Duration of dizziness;Stool occult blood turning negative time;Hospitalization Days;TCM Syndrome Score;Assessment of Clinical Efficacy in Traditional Chinese Medicine;Adverse Event;

Countries

China

Contacts

Public ContactBian Zhiyuan

Nanning Wuming District Traditional Chinese Medicine Hospital

764560084@qq.com18777106621

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026